Braunodin B. Brown - instructions for use, dose, side effects, contraindications

Povidone iodine is an antiseptic that is an iodine and povidone complex effective at a pH of 2 to 7. The bactericidal effect is due to the free active iodine that is released from the povidone-iodine complex in the ointment. Free iodine as a strong oxidant reacts at the molecular level with insoluble fatty acids and practically not oxidizing SH- and OH-groups of amino acids in the composition of enzymes and the basic structural components of bacteria, both gram-positive and gram-negative, mycobacteria, fungi, especially the genus Candida (Candida), various viruses and some protozoa. However, in order to completely inactivate some viruses and bacterial spores, a sufficiently long period of drug exposure is necessary.

There are no known cases of development of resistance in microorganisms with long-term use of povidone-iodine.

Pharmacokinetics:

After the application of the ointment, some absorption of iodine is possible, which must be taken into account depending on the location, amount and duration of the drug.If small amounts of the drug are applied to undamaged skin, then the resorption of iodine is negligible. A high level of absorption may be the result of prolonged use of drugs containing povidone-iodine, on extensive wounds and burns. As a result, a temporary increase in the iodine content in the blood is observed. In people with a healthy thyroid, higher levels of iodine do not result in clinically significant changes in the thyroid status. In normal iodine metabolism processes, excess iodine is removed through the kidneys.

Indications:

Post-traumatic and postoperative wounds of various locations, burns, trophic ulcers, pressure sores.

Infections of the skin with different etiologies, including infectious dermatitis and eczema.

Damage to the skin of various origins (maceration, abrasions, bruises).

Contraindications:

Hypersensitivity to the components of the drug.

Thyroid dysfunction (thyrotoxicosis).

Thyroid adenoma.

Herpetiform dermatitis of Dühring.

Simultaneous use of radioactive iodine.

Preterm, newborns and children under 6 months.

Carefully:

Chronic renal failure.

Pregnancy and lactation:

The drug is not recommended to use from the third month of pregnancy and during breastfeeding.

It is possible to use an ointment in pregnant women before the ninth week of pregnancy, when the expected benefit of treatment with the drug exceeds the possible risk of complications.

Dosing and Administration:

Outwardly.

The drug is applied to the affected surface one to several times a day until the symptoms of inflammation disappear. If necessary, use bandages, gauze tampons and turundas.

The multiplicity and duration of the application of the ointment depends on the course of the wound process. The course of treatment is 5-10 days.

Side effects:

Hypersensitivity reactions to the drug are possible: allergic reactions of delayed type (itching, redness of the skin, blisters) or allergic reactions of immediate type (anaphylactoid reactions).

Prolonged use of the drug (more than 7-10 days) and application on large skin surfaces, extensive wounds due to absorption can cause iodine effects ("metallic" taste in the mouth, increased salivation and lacrimation, edema of the mucous membranes) and systemic reactions (metabolic acidosis, hyponatremia ,impaired renal function and thyroid gland), at the appearance of which it is necessary to stop using the drug and consult a doctor.

Overdose:

With intensive absorption of iodine for a long period, the following symptoms can be noted: tachycardia, an excited state, a tremor and a headache. In this case, stop using the drug immediately and consult a doctor.

Interaction:

The drug is incompatible with the salts of alkaloids (celandine), tannic acid (tannin), salicylic acid, silver salts, bismuth, taurolidine and hydrogen peroxide.

In the presence of blood and pus, the drug binds to proteins and other organic compounds, so that its bactericidal activity may decrease. In this case it is recommended to increase the frequency / frequency of its application.

The simultaneous use of povidone iodine and topical preparations containing enzymes can promote oxidation and inhibition of their enzymatic activity.

Povidone-iodine has a synergistic effect with lithium preparations, as a result of which, with their long-term joint application, reversible oppression of thyroid function is possible.Therefore, patients who constantly take lithium drugs should avoid prolonged application of povidone-iodine on large surfaces.

The drug can lead to false-positive results in some diagnostic tests: the determination of hemoglobin or sugar in the urine and stool, the study of thyroid function, etc. Examination of the thyroid gland in this case should be carried out no earlier than 1-2 weeks after the end of treatment with povidone-iodine.

Special instructions:

Avoid contact with eyes.

Effect on the ability to drive transp. cf. and fur:

Not found.

Form release / dosage:

Ointment for external use, 10%.

Packaging:

For 20 g, 100 g and 250 g in a laminate tube with a bud.

For 250 g in a polypropylene jar with a winding polyethylene lid.

Tube for 20 g, 100 g and 250 g together with instructions for use in a cardboard bundle.

For 6 cans of 250 grams together with instructions for use in an appropriate quantity in a cardboard box (for hospitals).

Storage conditions:

Store at a temperature of 2 ° C to 25 ° C in a dark place.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiration date printed on the package.

After opening the banks, the drug should be stored for no more than 6 months, but not later than the expiry date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-000935

Date of registration:18.10.2011

Expiration Date:18.10.2016

Date of cancellation:2016-10-25

The owner of the registration certificate:B. Brown Mehlungen AGB. Brown Mehlungen AG Germany

Manufacturer: & nbsp

B. BRAUN MELSUNGEN, AG Germany

Representation: & nbspB. Brown Medikal, Open CompanyB. Brown Medikal, Open Company

Information update date: & nbsp23.02.2017

Illustrated instructions

Instructions

Braunodin B. Brown (Braunodin B.Braun)